Your browser doesn't support javascript.
loading
Loss of one copy of Zfp148 reduces lesional macrophage proliferation and atherosclerosis in mice by activating p53.
Sayin, Volkan I; Khan, Omar M; Pehlivanoglu, Lara E; Staffas, Anna; Ibrahim, Mohamed X; Asplund, Annika; Agren, Pia; Nilton, Anna; Bergström, Göran; Bergo, Martin O; Borén, Jan; Lindahl, Per.
Affiliation
  • Sayin VI; From the Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine (V.I.S., L.E.P., A.A., P.Å., A.N., G.B., J.B., P.L.), Department of Biochemistry, Institute of Biomedicine (V.I.S., P.L.), and Department of Molecular and Clinical Medicine/Sahlgrenska Cancer Center,
  • Khan OM; From the Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine (V.I.S., L.E.P., A.A., P.Å., A.N., G.B., J.B., P.L.), Department of Biochemistry, Institute of Biomedicine (V.I.S., P.L.), and Department of Molecular and Clinical Medicine/Sahlgrenska Cancer Center,
  • Pehlivanoglu LE; From the Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine (V.I.S., L.E.P., A.A., P.Å., A.N., G.B., J.B., P.L.), Department of Biochemistry, Institute of Biomedicine (V.I.S., P.L.), and Department of Molecular and Clinical Medicine/Sahlgrenska Cancer Center,
  • Staffas A; From the Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine (V.I.S., L.E.P., A.A., P.Å., A.N., G.B., J.B., P.L.), Department of Biochemistry, Institute of Biomedicine (V.I.S., P.L.), and Department of Molecular and Clinical Medicine/Sahlgrenska Cancer Center,
  • Ibrahim MX; From the Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine (V.I.S., L.E.P., A.A., P.Å., A.N., G.B., J.B., P.L.), Department of Biochemistry, Institute of Biomedicine (V.I.S., P.L.), and Department of Molecular and Clinical Medicine/Sahlgrenska Cancer Center,
  • Asplund A; From the Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine (V.I.S., L.E.P., A.A., P.Å., A.N., G.B., J.B., P.L.), Department of Biochemistry, Institute of Biomedicine (V.I.S., P.L.), and Department of Molecular and Clinical Medicine/Sahlgrenska Cancer Center,
  • Agren P; From the Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine (V.I.S., L.E.P., A.A., P.Å., A.N., G.B., J.B., P.L.), Department of Biochemistry, Institute of Biomedicine (V.I.S., P.L.), and Department of Molecular and Clinical Medicine/Sahlgrenska Cancer Center,
  • Nilton A; From the Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine (V.I.S., L.E.P., A.A., P.Å., A.N., G.B., J.B., P.L.), Department of Biochemistry, Institute of Biomedicine (V.I.S., P.L.), and Department of Molecular and Clinical Medicine/Sahlgrenska Cancer Center,
  • Bergström G; From the Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine (V.I.S., L.E.P., A.A., P.Å., A.N., G.B., J.B., P.L.), Department of Biochemistry, Institute of Biomedicine (V.I.S., P.L.), and Department of Molecular and Clinical Medicine/Sahlgrenska Cancer Center,
  • Bergo MO; From the Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine (V.I.S., L.E.P., A.A., P.Å., A.N., G.B., J.B., P.L.), Department of Biochemistry, Institute of Biomedicine (V.I.S., P.L.), and Department of Molecular and Clinical Medicine/Sahlgrenska Cancer Center,
  • Borén J; From the Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine (V.I.S., L.E.P., A.A., P.Å., A.N., G.B., J.B., P.L.), Department of Biochemistry, Institute of Biomedicine (V.I.S., P.L.), and Department of Molecular and Clinical Medicine/Sahlgrenska Cancer Center,
  • Lindahl P; From the Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine (V.I.S., L.E.P., A.A., P.Å., A.N., G.B., J.B., P.L.), Department of Biochemistry, Institute of Biomedicine (V.I.S., P.L.), and Department of Molecular and Clinical Medicine/Sahlgrenska Cancer Center,
Circ Res ; 115(9): 781-9, 2014 Oct 10.
Article in En | MEDLINE | ID: mdl-25212213
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Aortic Diseases / Transcription Factors / Transcriptional Activation / Tumor Suppressor Protein p53 / Macrophages, Peritoneal / Cell Proliferation / DNA-Binding Proteins / Atherosclerosis / Cell Cycle Checkpoints Type of study: Etiology_studies / Prognostic_studies Limits: Animals / Humans Language: En Journal: Circ Res Year: 2014 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Aortic Diseases / Transcription Factors / Transcriptional Activation / Tumor Suppressor Protein p53 / Macrophages, Peritoneal / Cell Proliferation / DNA-Binding Proteins / Atherosclerosis / Cell Cycle Checkpoints Type of study: Etiology_studies / Prognostic_studies Limits: Animals / Humans Language: En Journal: Circ Res Year: 2014 Type: Article